| Quarterly Financials | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
Revenue  | 178 | 198 | 193 | 203 | 205 | 225 | 225 | 210 | 146 | 291 | 279 | 294 | 346 | 308 | 296 | 312 | 283 | 305 | 292 | 284 | 280 | 310 | 293 | 334 | 316 | 353 | 325 | 352 | 394 | 430 |
| Expenses | 132 | 146 | 142 | 145 | 156 | 161 | 159 | 173 | 131 | 198 | 188 | 195 | 224 | 212 | 218 | 231 | 211 | 221 | 215 | 212 | 214 | 234 | 226 | 251 | 235 | 260 | 251 | 283 | 296 | 321 |
| EBITDA | 46 | 53 | 51 | 58 | 49 | 64 | 66 | 37 | 15 | 94 | 90 | 99 | 122 | 96 | 78 | 81 | 72 | 83 | 77 | 72 | 66 | 76 | 67 | 83 | 81 | 93 | 75 | 69 | 97 | 109 |
| Operating Profit % | 25 % | 25 % | 26 % | 28 % | 24 % | 28 % | 29 % | 16 % | 8 % | 32 % | 32 % | 33 % | 31 % | 30 % | 26 % | 24 % | 24 % | 26 % | 25 % | 25 % | 23 % | 24 % | 22 % | 24 % | 25 % | 26 % | 22 % | 18 % | 23 % | 25 % |
| Depreciation | 5 | 5 | 5 | 5 | 8 | 9 | 11 | 11 | 10 | 11 | 11 | 14 | 13 | 15 | 17 | 18 | 21 | 22 | 23 | 23 | 21 | 22 | 25 | 26 | 26 | 27 | 28 | 29 | 31 | 32 |
| Interest | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 6 | 3 | 5 | 6 | 8 | 7 | 6 | 6 | 6 | 6 | 5 | 6 | 5 | 5 | 5 | 5 | 5 | 6 |
| Profit Before Tax | 42 | 48 | 46 | 52 | 39 | 53 | 53 | 23 | 4 | 81 | 78 | 82 | 103 | 78 | 56 | 57 | 43 | 55 | 48 | 42 | 39 | 48 | 37 | 51 | 51 | 61 | 42 | 36 | 61 | 71 |
| Tax | 14 | 18 | 14 | 17 | 12 | 10 | 11 | 8 | 1 | 21 | 19 | 20 | 28 | 19 | 15 | 16 | 9 | 14 | 12 | 8 | 10 | 13 | 10 | 14 | 13 | 15 | 11 | 7 | 16 | 18 |
| Net Profit | 27 | 30 | 31 | 35 | 27 | 43 | 42 | 16 | 3 | 61 | 59 | 61 | 75 | 58 | 41 | 40 | 34 | 41 | 36 | 34 | 29 | 36 | 27 | 37 | 38 | 47 | 32 | 29 | 45 | 53 |
| EPS in ₹ | 4.83 | 6.14 | 6.26 | 6.87 | 5.34 | 8.57 | 8.38 | 3.09 | 0.57 | 11.88 | 11.50 | 12.05 | 14.65 | 11.39 | 8.02 | 7.81 | 6.53 | 7.88 | 6.99 | 6.51 | 5.62 | 6.92 | 5.30 | 7.11 | 7.41 | 9.08 | 6.12 | 5.69 | 8.70 | 10.17 |
Metropolis Healthcare
Metropolis Healthcare
1,825.80
+12.40
(0.68%)
Market Cap
9,461.66 Cr
PE Ratio
59.10
Volume
40,753.00
Day High - Low
1,835.40 - 1,790.10
52W High-Low
2,263.00 - 1,315.00
Key Fundamentals
Market Cap
9,461.66 Cr
EPS
28.29
PE Ratio
59.10
PB Ratio
6.55
Book Value
276.37
EBITDA
318.10
Dividend Yield
0.00 %
Industry
Healthcare Services Sector
Healthcare Service Provider Return on Equity
10.90
Debt to Equity
0.17
Analyst Rating and Forecast
- By Refinitiv from18 analysts
Actual
Company News
View All News
Metropolis Healthcare Allots 9,960 Equity Shares
Jan 13, 2026
Jan 13, 2026Metropolis Healthcare Limited allotted 9,960 equity shares at ₹2 per share under its RSU Plan 2020, with 50% shares subject to one-year lock-in period starting January 13, 2026.
Metropolis Healthcare launches Centre for Genomics, plans to expand test menu from 220 to 500 tests over next two years. Company targets 13-15% organic growth in FY26-27 with specialty tests contributing 38% of revenue.
Metropolis Healthcare launches genomics centreJan 13, 2026
Jan 13, 2026Metropolis Healthcare launches Centre of Genomics with CAP-accredited labs in Mumbai and Delhi NCR, plans to expand genomic portfolio to 500+ tests over 2-3 years from current 220+ validated assays.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,401.40 | #1 23,480.60 | 42.69 | #1 2,554.80 | 11.28 | #1 492 | 16.36 | 39.81 | |
968.40 | 9,947.88 | 67.40 | 699.70 | 23.06 | 144 | 2.85 | 46.85 | |
1,825.80 | #3 9,461.66 | #7 59.10 | #2 1,346.30 | #9 10.64 | #2 146 | #6 13.28 | 37.41 | |
453.50 | 7,217.98 | 55.59 | 702.20 | 20.80 | 91 | 81.06 | 42.47 | |
511.90 | 5,136.44 | 76.11 | 769.90 | 33.97 | 67 | - | 58.35 | |
710.70 | 2,305.42 | 27.43 | 742.70 | 16.70 | 78 | 22.45 | 45.02 | |
1,592.70 | 1,366.96 | 28.54 | 111.60 | 28.72 | 48 | 0.67 | 62.69 | |
259.80 | 1,353.06 | 43.77 | 255.90 | 15.11 | 31 | -13.73 | 40.78 | |
502.60 | 982.21 | #1 23.45 | 147.80 | #1 134.60 | 19 | #1 760.87 | 45.23 | |
291.55 | 927.44 | -105.09 | 1,170.80 | -18.47 | -134 | 90.05 | 40.74 |
Automatic Screeners on ScanX
Growth Rate
Revenue Growth
10.64 %
Net Income Growth
13.23 %
Cash Flow Change
-0.50 %
ROE
-6.76 %
ROCE
-11.55 %
EBITDA Margin (Avg.)
-1.42 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 530 | 553 | 752 | 1,004 | 1,530 | 1,502 | 1,555 | 1,867 |
| Fixed Assets | 207 | 213 | 296 | 343 | 1,059 | 1,121 | 1,177 | 1,447 |
| Current Assets | 300 | 305 | 397 | 609 | 393 | 303 | 316 | 346 |
| Capital Work in Progress | 0 | 6 | 3 | 0 | 6 | 20 | 0 | 0 |
| Investments | 102 | 33 | 14 | 10 | 16 | 15 | 55 | 71 |
| Other Assets | 221 | 301 | 439 | 651 | 450 | 347 | 323 | 349 |
| Total Liabilities | 530 | 553 | 752 | 1,004 | 1,530 | 1,502 | 1,555 | 1,867 |
| Current Liabilities | 91 | 125 | 170 | 204 | 302 | 265 | 246 | 294 |
| Non Current Liabilities | 11 | 8 | 58 | 92 | 341 | 246 | 210 | 238 |
| Total Equity | 429 | 420 | 525 | 708 | 888 | 991 | 1,099 | 1,335 |
| Reserve & Surplus | 405 | 409 | 513 | 696 | 876 | 978 | 1,086 | 1,313 |
| Share Capital | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | 4 | 14 | -1 | 18 | 8 | 56 | 279 | -321 | 3 | -6 | -23 |
| Investing Activities | -56 | 96 | -86 | 1 | 36 | -104 | 63 | -736 | 48 | -89 | -199 |
| Operating Activities | 70 | 91 | 102 | 104 | 90 | 215 | 249 | 253 | 247 | 264 | 263 |
| Financing Activities | -10 | -174 | -17 | -87 | -118 | -55 | -33 | 163 | -292 | -181 | -87 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 |
| Promoter | 50.38 % | 50.37 % | 50.33 % | 49.50 % | 49.79 % | 49.79 % | 49.76 % | 49.76 % | 49.75 % | 49.75 % | 49.74 % | 49.74 % | 49.67 % | 49.62 % | 49.43 % | 49.40 % | 48.90 % | 48.89 % | 48.89 % | 48.88 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 24.29 % | 0.00 % | 18.90 % | 18.25 % | 18.56 % | 16.73 % | 15.29 % | 12.83 % | 12.52 % | 11.69 % |
| DIIs | 15.34 % | 14.22 % | 11.77 % | 10.63 % | 15.32 % | 13.85 % | 11.88 % | 13.30 % | 13.64 % | 14.47 % | 16.86 % | 20.28 % | 24.86 % | 27.43 % | 28.02 % | 30.00 % | 30.30 % | 32.40 % | 33.10 % | 34.73 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 3.95 % | 3.98 % | 4.24 % | 6.50 % | 9.14 % | 9.26 % | 9.45 % | 9.73 % | 8.53 % | 8.15 % | 7.78 % | 6.63 % | 5.24 % | 4.07 % | 3.54 % | 3.34 % | 3.84 % | 4.16 % | 3.69 % | 3.87 % |
| Others | 30.33 % | 31.43 % | 33.66 % | 33.37 % | 25.75 % | 27.10 % | 28.91 % | 27.21 % | 28.08 % | 27.62 % | 1.32 % | 23.35 % | 1.33 % | 0.63 % | 0.45 % | 0.53 % | 1.68 % | 1.72 % | 1.80 % | 0.83 % |
| No of Share Holders | 30,679 | 33,527 | 43,552 | 64,168 | 79,895 | 86,404 | 90,090 | 91,452 | 84,269 | 89,692 | 86,249 | 79,878 | 68,283 | 58,108 | 51,852 | 48,572 | 49,293 | 50,015 | 47,846 | 46,670 |
Dividend History
| Annual Cash Flows | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 0.00 | 13.26 | 8 | 8 | 8 | 8 | 4 | 0.00 | 0.00 |
| Dividend Yield (%) | 0.00 | 0.00 | 1.03 | 0.36 | 0.39 | 0.67 | 0.46 | 0.26 | 0.00 | 0.00 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 19 Feb 2021 |  Dividend | ₹ 8.00 /share | 17 Feb 2021 | 2,163.55 | 2,011.85 |
| 22 Feb 2022 | Dividend | ₹ 8.00 /share | 21 Feb 2022 | 2,459.95 | 1,976.10 |
| 23 Feb 2023 | Dividend | ₹ 8.00 /share | 23 Feb 2023 | 1,289.35 | 1,348.60 |
| 17 Nov 2023 | Dividend | ₹ 4.00 /share | 17 Nov 2023 | 1,472.25 | 1,606.85 |
| 21 Aug 2024 |  Annual General Meeting | NA | 21 Aug 2024 | 2,098.30 | 2,091.55 |
| 08 Nov 2024 |  Quarterly Result Announcement | NA | 08 Nov 2024 | 2,119.10 | 2,112.60 |
| 04 Feb 2025 | Quarterly Result Announcement | NA | 04 Feb 2025 | 1,708.90 | 1,757.75 |
| 13 May 2025 | Quarterly Result Announcement | NA | 13 May 2025 | 1,694.80 | 1,712.30 |
| 07 Aug 2025 | Quarterly Result Announcement | NA | 07 Aug 2025 | 2,019.00 | 2,055.70 |
| 13 Aug 2025 | Annual General Meeting | NA | 13 Aug 2025 | 1,938.80 | 2,092.90 |
| 04 Nov 2025 | Quarterly Result Announcement | NA | 04 Nov 2025 | 1,953.20 | 2,004.45 |
| 11 Nov 2025 | Dividend | ₹ 4.00 /share | 11 Nov 2025 | 2,004.45 | 1,936.05 |
Announcements
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSJan 13, 2026
Jan 13, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJan 13, 2026
Jan 13, 2026Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 08, 2026
Jan 08, 2026 Business Update For Q3FY26Jan 05, 2026
Jan 05, 2026Closure of Trading WindowDec 31, 2025
Dec 31, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 24, 2025
Nov 24, 2025Intimation Of Cancellation Of Analyst / Institutional Investor Meeting Scheduled On November 21 2025Nov 21, 2025
Nov 21, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 12, 2025
Nov 12, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptNov 11, 2025
Nov 11, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeNov 06, 2025
Nov 06, 2025Update On Schedule Of Earnings Conference Call For The Quarter And Half Year Ended September 30 2025Nov 05, 2025
Nov 05, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 05, 2025
Nov 05, 2025Announcement under Regulation 30 (LODR)-Investor PresentationNov 04, 2025
Nov 04, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 04, 2025
Nov 04, 2025Corporate Action-Board approves DividendNov 04, 2025
Nov 04, 2025Unaudited Standalone And Consolidated Financial Results For The Quarter And Half Year Ended September 30 2025Nov 04, 2025
Nov 04, 2025Board Meeting Outcome for For The Meeting Held Today (November 04 2025)Nov 04, 2025
Nov 04, 2025Grant Of Stock BenefitsNov 04, 2025
Nov 04, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationOct 28, 2025
Oct 28, 2025Board Meeting Intimation for Considering And Approving The Un-Audited Standalone And Consolidated Financial Results For The Quarter And Half Year Ended September 30 2025 And Declaration Of Interim Dividend If Any For The Financial Year 2025-26Oct 28, 2025
Oct 28, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSOct 13, 2025
Oct 13, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 07, 2025
Oct 07, 2025Business Update For Q2FY26Oct 06, 2025
Oct 06, 2025Closure of Trading WindowSep 30, 2025
Sep 30, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseSep 18, 2025
Sep 18, 2025Announcement under Regulation 30 (LODR)-Updates on AcquisitionSep 18, 2025
Sep 18, 2025Announcement under Regulation 30 (LODR)-AcquisitionSep 16, 2025
Sep 16, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 10, 2025
Sep 10, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 10, 2025
Sep 10, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptAug 14, 2025
Aug 14, 2025Shareholder Meeting / Postal Ballot-Scrutinizers ReportAug 14, 2025
Aug 14, 2025Shareholder Meeting / Postal Ballot-Outcome of AGMAug 13, 2025
Aug 13, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeAug 08, 2025
Aug 08, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 08, 2025
Aug 08, 2025Update On Schedule Of Earnings Conference Call For The Quarter Ended June 30 2025Aug 07, 2025
Aug 07, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 07, 2025
Aug 07, 2025Announcement under Regulation 30 (LODR)-Investor PresentationAug 07, 2025
Aug 07, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 07, 2025
Aug 07, 2025Announcement under Regulation 30 (LODR)-AcquisitionAug 07, 2025
Aug 07, 2025Unaudited Standalone And Consolidated Financial Results For The Quarter Ended June 30 2025Aug 07, 2025
Aug 07, 2025Board Meeting Outcome for The Meeting Held Today (August 07 2025)Aug 07, 2025
Aug 07, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 01, 2025
Aug 01, 2025Board Meeting Intimation for Considering And Approving The Un-Audited Standalone And Consolidated Financial Results For The Quarter Ended June 30 2025Jul 31, 2025
Jul 31, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 23, 2025
Jul 23, 2025Letter To Shareholders Containing Weblink Of 25Th Annual General Meeting And Annual Report For The Financial Year 2024-25Jul 22, 2025
Jul 22, 2025Business Responsibility and Sustainability Reporting (BRSR)Jul 22, 2025
Jul 22, 2025Notice Of 25Th Annual General Meeting For The Financial Year 2024-25Jul 22, 2025
Jul 22, 2025Reg. 34 (1) Annual Report.Jul 22, 2025
Jul 22, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 21, 2025
Jul 21, 2025Disclosure Under Regulation 30 Of Listing RegulationsJul 18, 2025
Jul 18, 2025Mutual Fund Holdings
Technical Indicators
RSI(14)
Neutral 37.41
ATR(14)
Volatile 65.12
STOCH(9,6)
Neutral 30.48
STOCH RSI(14)
Oversold 13.24
MACD(12,26)
Bearish -8.21
ADX(14)
Weak Trend 12.18
UO(9)
Bearish 40.98
ROC(12)
Downtrend And Accelerating -10.66
WillR(14)
Oversold -91.67
About Metropolis Healthcare
Metropolis Healthcare Limited is an Indian diagnostic services company operating across India and Africa. Founded in 1980 as a pathology partnership, it has evolved into a public company offering a wide range of clinical laboratory tests and profiles. The company operates through a hub and spoke model with 115 clinical...more
Listing Date
15 Apr, 2019(6 Years,
43 days)
Chairperson NameAmeera Sushil Shah
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
